ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Ä¡·áÁ¦º°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Influenza Treatment Market Size, Share & Trends Analysis Report By Treatment (Peramivir, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1405863
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 130 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,152,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,522,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,262,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀåÀº 2024-2030³â CAGR 1.18%·Î È®´ëÇϸç, 2030³â±îÁö´Â 64¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

µ¶°¨ ½ÃÀåÀÇ ¼ºÀåÀº µ¶°¨ À¯º´·ü Áõ°¡¿Í ÇÔ²² µ¶°¨ Ä¡·á¸¦ À§ÇÑ È¿À²ÀûÀÎ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷Àº FDAÀÇ Áö¼ÓÀûÀÎ µ¶°¨ Ä¡·áÁ¦ ½ÂÀÎ ³ë·Â¿¡ µû¶ó Á¤È®ÇÑ ¾à¹° ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »õ·Î¿î Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇØ Áö¼ÓÀûÀ¸·Î ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, Àü ¼¼°è Ä¡·áÁ¦¿¡ ´ëÇÑ ²÷ÀÓ¾ø´Â ¼ö¿ä°¡ Àüü ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ °èÀý¼º µ¶°¨ ¹× È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ »õ·Î¿î Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, CDC¿¡ µû¸£¸é 2010-2020³â ¹Ì±¹ÀÇ µ¶°¨ ºÎ´ãÀº ¿¬°£ 9¹é¸¸¿¡¼­ 4,100¸¸ ¸íÀÇ Áúº´, 140,000-710,000¸íÀÇ ÀÔ¿ø, 12,000-52,000¸íÀÇ »ç¸ÁÀ» ÃÊ·¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¸¶Âù°¡Áö·Î ¿¹ºñ Á¶»ç °á°ú¿¡ µû¸£¸é 2021-2022³â ¾à 900¸¸ ¸íÀÌ Áõ»óÀ» È£¼ÒÇϰí, ¾à 400¸¸ ¸íÀÌ Áø·á¸¦ ¹Þ°í, 10¸¸ ¸íÀÌ ÀÔ¿øÇϰí, 5,000¸íÀÌ »ç¸ÁÇÑ °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¹ÙÀÌ·¯½º °¨¿°¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·áÁ¦ÀÇ ½ÂÀΰú ÇâÈÄ Ãâ½Ã°¡ ¿¹Á¤µÇ¾î ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 8¿ù ·Î½´(Roche)´Â 48½Ã°£ µ¿¾È Áõ»óÀÌ ÀÖ´Â 5-12¼¼ ¾î¸°À̵éÀÇ ±Þ¼º µ¶°¨ Ä¡·á¿¡ »ç¿ëµÇ´Â Xofluza(baloxavir marboxil)°¡ ¹Ì±¹ FDA ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¶ÇÇÑ ¾÷°è ´ë±â¾÷Àº 2-3³â »çÀÌ¿¡ ¹ÙÀÌ·¯½º °¨¿°¿¡ ´ëÇÑ ¸î °¡Áö ½Å¾àÀ» ¹ßÇ¥ÇÏ¿© ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ´Ù¸¥ ¼Ò±Ô¸ð ȸ»çµéÀÌ ´õ Å« ¸ÅÃâ Á¡À¯À²À» È®º¸Çϱâ À§ÇØ ½Å¾àÀ» °³¹ßÇØ¾ß ÇÒ Çʿ伺¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ COVID-19 ÆÒµ¥¹ÍÀº ½ÃÀå ¼ºÀåÀ» Å©°Ô ÃËÁøÇß½À´Ï´Ù. ÆÒµ¥¹Í ±â°£ Áß Áúº´À» È¿°úÀûÀ¸·Î °ü¸®ÇØ¾ß ÇÒ Çʿ伺À¸·Î ÀÎÇØ ½ÅÁ¾ Äڷγª ¹ÙÀÌ·¯½º¿¡ ´ëÀÀÇϱâ À§ÇÑ ±¤¹üÀ§ Ç×¹ÙÀÌ·¯½ºÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇß½À´Ï´Ù. ·½µ¥½Ãºñ¸£, ÆÄºñÇǶóºñ¸£, ¿À¼¿Å¸¹Ìºñ¸£ ¹× ´Ù¾çÇÑ º´¿ë¿ä¹ý°ú °°Àº ¾à¹°ÀÌ COVID-19 Ä¡·á¿¡ ³Î¸® ó¹æµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¢±¹ Á¤ºÎ´Â COVID-19 Ä¡·áÁ¦ °³¹ßÀ» ÃËÁøÇϱâ À§ÇØ Á¦¾àȸ»ç¿¡ ´õ ¸¹Àº ÀÚ±ÝÀ» ¹èÁ¤Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ Á¤ºÎ´Â 2021³â 6¿ù Ç×¹ÙÀÌ·¯½ºÁ¦ ¹ß°ß, Á¦Á¶ ¹× °³¹ßÀ» °¡¼ÓÈ­Çϱâ À§ÇØ 30¾ï ´Þ·¯ ÀÌ»óÀ» ÅõÀÚÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù. ¹ßº´·üÀÌ °è¼Ó »ó½ÂÇÏ°í ¿¬±¸°³¹ß ³ë·ÂÀÌ °­È­µÊ¿¡ µû¶ó Ç×¹ÙÀÌ·¯½ºÁ¦ ¼ö¿ä´Â ÇâÈÄ 2 - 3³âµ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ÁÖ¿ä ÁøÃâ±â¾÷Àº ±¹Á¦ÀûÀÎ ¹ßÀÚÃ븦 È®ÀåÇÏ°í µ¶°¨ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °æÀïÀû ÁöÀ§¸¦ À¯ÁöÇϱâ À§ÇØ Á¦Ç° Ãâ½Ã, Á¦ÈÞ ¹× Çù·Â, M&A µî ´Ù¾çÇÑ Àü·«À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 11¿ù ½Ã¿À³ë±â(Shionogi)ÀÇ XOFLUZA(Baloxavir Marboxil)°¡ µ¶°¨ ¿¹¹æ¾àÀ¸·Î FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ¸¶Âù°¡Áö·Î 2021³â 2¿ù, FDA´Â ¹ÙÀÌ¿ÀÅ©¸®½ºÆ® ÆÄ¸¶½´Æ¼Äýº(BioCryst Pharmaceuticals)ÀÇ Á¦Ç°ÀÎ Æä¶ó¹Ìºñ¸£ ÁÖ»çÁ¦ ¶óÇǹä(Rapivab)ÀÇ ½ÂÀÎÀ» È®´ëÇß½À´Ï´Ù. ÀÌ Á¦Ç°Àº »ýÈÄ 6°³¿ù ÀÌ»ó, 2ÀÏ ÀÌ»ó Áõ»óÀÌ Áö¼ÓµÇ´Â ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÕº´Áõ ¾ø´Â ±Þ¼º µ¶°¨ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

µ¶°¨Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå : Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå : ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

Á¦4Àå ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå : Ä¡·á ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå : Åõ¿© °æ·Î ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå : À¯Åë ä³Î ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ÀÎÇ÷翣ÀÚ Ä¡·á ½ÃÀå : Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦8Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Influenza Treatment Market Growth & Trends:

The global influenza treatment market is expected to reach USD 6.44 billion by 2030, expanding at a CAGR of 1.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the rising prevalence of influenza aided by the rising need for efficient therapeutics to treat the condition. Furthermore, key players are constantly focusing on developing novel therapeutics to meet the rising demand for precise medication with constant initiative by the FDA for approval of influenza treatment drugs. As a result of which, the constant demand for treatment globally is fueling the growth of the overall market.

Additionally, the rising prevalence of seasonal flu and respiratory diseases has boosted the demand for novel therapeutics. According to CDC, it is estimated that the burden of flu in the U.S. had resulted in 9 million -41 million illnesses, 140,000 - 710,000 hospitalizations, and 12,000 - 52,000 deaths yearly between 2010 and 2020. Similarly, according to preliminary results around 9 million individuals had symptomatic illnesses, and approximately 4 million medical visits, 100,000 hospitalizations, and 5 thousand deaths were reported from 2021 to 2022.

The market growth is expected to be driven by the increasing approval and upcoming commercialization of innovative medications for viral infections. For instance, in August 2022, Roche announced the U.S. FDA approval for Xofluza (baloxavir marboxil), used for the treatment of acute influenza in children aged 5 to 12 years who have been symptomatic for 48 hours. Additionally, prominent players in the industry have introduced several novel medicines for viral infections within the span of 2 to 3 years propelling the need for the development of novel medication by other small players operating in the market in order to generate significant revenue share.

Moreover, the COVID-19 pandemic has significantly boosted the growth of the market. During the pandemic, the demand for broad-spectrum antiviral drugs to combat the novel coronavirus has surged due to the need to manage the disease effectively. Medications like Remdesivir, favipiravir, oseltamivir, and various combination therapies have become widely prescribed for treating COVID-19. Additionally, governments are allocating greater funding to pharmaceutical companies to expedite the development of novel therapeutics against COVID-19. For instance, in June 2021, the U.S. government announced an investment of over USD 3 billion to accelerate the discovery, manufacturing, and development of antiviral medicines. As the incidence of the disease continues to rise and research and development efforts intensify, the demand for antiviral drugs is expected to increase in the next 2 to 3 years.

Furthermore, the key participants are engaged in various strategies such as product launches, partnerships & collaborations, and mergers & acquisitions, to expand their global footprints and maintain their competitive position in the influenza treatment market. For instance, in November 2020, Shionogi's XOFLUZA (Baloxavir Marboxil) received FDA approval for the prevention of influenza. Similarly, in February 2021, FDA expanded the approval of Rapivab which is a peramivir injection, a product of BioCryst Pharmaceuticals. The product is extensively used for treating acute uncomplicated influenza in 6 months of age & older patients who have been symptomatic for 2 days.

Influenza Treatment Market Report Highlights:

Table of Contents

Chapter 1. Influenza Treatment Market: Methodology and Scope

Chapter 2. Influenza Treatment Market: Executive Summary

Chapter 3. Influenza Treatment Market Variables, Trends, & Scope

Chapter 4. Influenza Treatment Market: Treatment Estimates & Trend Analysis

Chapter 5. Influenza Treatment Market: Route of Administration Estimates & Trend Analysis

Chapter 6. Influenza Treatment Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. Influenza Treatment Market: Regional Business Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â